Current Rating Overview
MarketsMOJO’s Buy rating for Fredun Pharmaceuticals Ltd is based on a comprehensive evaluation of four key parameters: Quality, Valuation, Financial Trend, and Technicals. This rating indicates a positive outlook for the stock, suggesting that it presents an attractive opportunity for investors seeking growth within the Pharmaceuticals & Biotechnology sector. The company’s Mojo Score currently stands at 74.0, reflecting a solid improvement from its previous score of 67, which corresponded to a Hold rating.
Quality Assessment
As of 25 April 2026, Fredun Pharmaceuticals holds an average quality grade. This reflects a stable operational foundation with consistent growth in core business areas. The company has demonstrated healthy long-term growth, with net sales increasing at an annual rate of 38.09% and operating profit expanding at an impressive 58.31%. These figures underscore the company’s ability to generate sustainable revenue and profitability, which is a crucial factor in the quality assessment.
Valuation Considerations
The valuation grade for Fredun Pharmaceuticals is fair, indicating that the stock is reasonably priced relative to its earnings and growth prospects. The company’s return on capital employed (ROCE) is currently 20.2%, which is a strong indicator of efficient capital utilisation. Additionally, the enterprise value to capital employed ratio stands at 4.2, suggesting the stock is trading at a discount compared to its peers’ historical valuations. The PEG ratio of 0.6 further supports the view that the stock is undervalued relative to its earnings growth, making it an appealing choice for value-conscious investors.
Financial Trend and Performance
The financial trend for Fredun Pharmaceuticals is very positive. The latest data shows the company has declared positive results for seven consecutive quarters, with operating profit growth reaching 99.09%. Quarterly net sales have surged by 56.70% to ₹160.93 crores, while profit before tax excluding other income (PBT less OI) hit a high of ₹14.00 crores. Operating profit before depreciation and interest (PBDIT) also reached a record ₹26.34 crores. These robust financials highlight the company’s strong earnings momentum and operational efficiency.
Moreover, the stock has delivered exceptional returns, with a one-year return of 208.07% as of 25 April 2026. This performance significantly outpaces the broader market benchmarks, including the BSE500 index, which the stock has outperformed over the last three years, one year, and three months. The company’s profits have risen by 81.2% over the past year, reinforcing the strength of its financial trajectory.
Technical Analysis
From a technical perspective, Fredun Pharmaceuticals is rated bullish. The stock’s recent price movements reflect strong upward momentum, supported by a 0.41% gain on the latest trading day and a 25.73% increase over the past month. The sustained positive trend is indicative of growing investor confidence and favourable market sentiment, which complements the fundamental strengths of the company.
Promoter Confidence
Another important factor supporting the Buy rating is the rising promoter confidence. Promoters have increased their stake by 1.11% over the previous quarter, now holding 44.17% of the company. This increased ownership signals strong belief in the company’s future prospects and aligns management interests with those of shareholders, which is often viewed positively by the market.
Implications for Investors
For investors, the Buy rating suggests that Fredun Pharmaceuticals Ltd is well-positioned for continued growth and value creation. The combination of solid quality metrics, fair valuation, very positive financial trends, and bullish technical indicators provides a compelling case for considering this stock as part of a diversified portfolio. The company’s strong fundamentals and market-beating returns highlight its potential to deliver attractive risk-adjusted returns over the medium to long term.
Fresh entry alert! This Small Cap from Electronics & Appliances sector is already turning heads in our Top 1% club. Get ahead of the market now!
- - New Top 1% entry
- - Market attention building
- - Early positioning opportunity
Sector and Market Context
Operating within the Pharmaceuticals & Biotechnology sector, Fredun Pharmaceuticals benefits from a dynamic industry environment characterised by innovation, regulatory developments, and growing demand for healthcare products. The company’s microcap status offers investors exposure to a niche segment with significant growth potential, albeit with higher volatility compared to larger peers. Its recent performance and fundamentals suggest it is navigating this landscape effectively, capitalising on market opportunities while maintaining operational discipline.
Summary of Key Metrics as of 25 April 2026
To summarise, the stock’s key metrics as of today include:
- Mojo Score: 74.0 (Buy grade)
- Net Sales growth (annualised): 38.09%
- Operating Profit growth (annualised): 58.31%
- Return on Capital Employed (ROCE): 20.2%
- Enterprise Value to Capital Employed: 4.2
- PEG Ratio: 0.6
- Promoter Holding: 44.17%, increased by 1.11% last quarter
- Stock Returns: 1Y +208.07%, YTD +34.29%, 3M +43.52%
These figures collectively underpin the Buy rating and highlight the company’s strong position in the current market environment.
Conclusion
Fredun Pharmaceuticals Ltd’s Buy rating by MarketsMOJO reflects a well-rounded assessment of its quality, valuation, financial health, and technical outlook as of 25 April 2026. Investors looking for exposure to a growing pharmaceutical company with robust earnings momentum and attractive valuation metrics may find this stock a compelling addition to their portfolio. The company’s consistent positive results, promoter confidence, and market-beating returns further reinforce its appeal in the current investment landscape.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
